A LinkedIn post from ThinkCyte highlights an upcoming live webinar organized with Scripps Research that focuses on label-free cell analysis using AI-driven, morphology-based sorting. The session is set to feature a live demonstration of the company’s VisionSort platform and will be led by ThinkCyte’s Head of Research, Dr. Romain Ballet.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the webinar will explore how Ghost Cytometry can enable high-throughput, label-free identification of cell subsets and uncover phenotypes without known biomarkers, while preserving cell viability for downstream assays. The content is positioned toward researchers in immunology, translational research, and drug discovery who are interested in integrating VisionSort into existing workflows.
For investors, the event suggests ongoing efforts by ThinkCyte to increase scientific adoption and validate its technology in collaboration with a high-profile research institution. Strong engagement from the webinar’s target audience could translate into greater market awareness and potential demand for the company’s platforms in cell analysis and sorting.
The collaboration with Scripps Research may also signal strategic positioning within advanced flow cytometry and AI-in-biology niches, where differentiated label-free capabilities can be a competitive advantage. If the technology demonstrates practical benefits in real-world case studies, it could support ThinkCyte’s prospects for partnerships, commercial deployments, and future revenue growth in drug discovery and regenerative medicine workflows.